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Given their roles in immune regulation, the expression of the nuclear receptor peroxisome proliferator-activated receptor γ
(PPARγ) 1 and 2 isoforms was investigated in human na¨ ıve (CD45RA+) and memory (CD45RO+) CD4+ T cells. Stimulation
of both types of cells via the CD3/CD28 pathway resulted in high expression of both PPARγ receptors as measured by real-time
PCR.TreatmentwiththePPARγ agonist,ciglitazone,increasedPPARγ1expressionbutdecreasedPPARγ2expressioninstimulated
na¨ ıve and memory cells. Furthermore, when present, the magnitude of both PPARγ receptors expression was lower in na¨ ıve cells,
perhaps suggesting a lower regulatory control of these cells. Similar proﬁles of selected proinﬂammatory cytokines were expressed
bythetwocelltypesfollowingstimulation.TheinductionofPPARγ1andsuppressionofPPARγ2expressionsinna¨ ıveandmemory
CD4+ T cells in the presence of ciglitazone suggest that the PPARγ subtypes may have diﬀerent roles in the regulation of T-cell
function.
1.Introduction
Peripheral CD4+ T cells can be divided into two broad func-
tional groups based on their expression of distinct isoforms
of the CD45 surface molecule, CD45RA representing na¨ ıve
CD4+ T cells and CD45RO representing memory CD4+ T
cells [1]. Memory CD4+ T cells require a shorter lag time
to proliferate when they are stimulated by antigens and are
less dependent on costimulation than are na¨ ıve CD4+ T
cells [2]. On the other hand, na¨ ı v eC D 4 +Tc e l l sh a v eb e e n
reported to be the source of autoreactive lymphocytes in
multiple sclerosis [3, 4], suggesting a diﬀerential regulatory
mechanism for these cells.
T h epe r o x i s o m ep r o l i f e ra t o r - a ct i v a t e dr e c e p t o r s( P P A R s )
are ligand-activated receptors that belong to the nuclear
receptor superfamily [5]. Three isoforms of PPARs have
been identiﬁed and are encoded by separate genes, namely,
PPARα, γ,a n dβ/δ [6, 7]. PPARγ is predominantly expressed
in adipose tissue, colon, spleen, adrenal gland, and mono-
cytes/macrophage [6, 7]. This isoform is further divided into
four subtypes: PPARγ1, γ2, γ3, and γ4 due to alternative
promoter use and RNA splicing [8]. PPARγ1, PPARγ3,
and PPARγ4 encode for the same protein product, while
the PPARγ2 protein contains an additional 28 amino acids
at its N-terminus. PPARγ ligands include the naturally
occurring arachidonic acid metabolite, 15-deoxy-D12,14-
prostaglandin J2(15d-PGJ2), aswellasthethiazolidinedione
(TZD) group of drugs such as ciglitazone and certain novel
non-TZD insulin-sensitizing agents [9, 10].
PPARγ expressedinmurineT-cellsplaysaregulatoryrole
in T-cell activation [11]. Previous experiments showed that
murine helper-T-cell clones and freshly isolated splenocytes
express PPARγ1b u tn o tP P A R γ2 mRNA and that 15d-
PGJ2 and ciglitazone inhibited the proliferative responses
and IL-2 production of these cells when stimulated with the
speciﬁc antigen and anti-CD3 antibodies, respectively [11].2 Clinical and Developmental Immunology
Similarly, it was reported that 15d-PGJ2 and troglitazone
suppressed IL-2 production of PHA-stimulated peripheral
blood T cells [12]. PPARγ has been shown to physically bind
to the transcription factors AP-1 and NFAT [12, 13], which
regulate the IL-2 promoter thus blocking their binding to the
promoter and hence inhibiting the transcription of the IL-2
gene.
These studies indicate an important immunoregulatory
role for PPARγ in T-cell function. It will, therefore, be
interesting to investigate whether na¨ ıve and memory CD4+
T cells behave in the same manner with regard to the expres-
sion of PPARγ and whether their activation modulate the
expression of the PPARγ receptor diﬀerently. It would also
beimportanttoexploretheimpactoncytokineexpressionin
these T-cell subsets upon activation of PPARγ, in particular
selected proinﬂammatory cytokines, which are important in
autoreactivity such as autoimmune diabetes [14].
Most studies on the role of PPARγ have used semi-
quantitative measurements to assess the mRNA level of the
receptor. Since subtle changes in PPARγ levels may result
in signiﬁcant changes to various downstream events as
postulated by other types of receptor-signaling molecules
[15], an accurate quantiﬁcation of PPARγ isoform levels
following cellular activation would need to be carried out.
We propose to study the expression of PPARγ1a n d
PPARγ2 in unstimulated and stimulated na¨ ıve and memory
CD4+ T-cell subsets using quantitative real-time PCR. To
further dissect the role of PPARγ1a n dP P A R γ2i ni m m u n e
activation, the PPARγ agonist, ciglitazone, was used to
modulate the activation status of these cell types and assess
the modulation of their expression levels as well as those of
selected proinﬂammatory cytokines in these cells.
2.MaterialsandMethods
2.1. Isolation of Na¨ ıve and Memory CD4+ T Cells from
Peripheral Blood. Peripheral blood collection has prior
approval from the Universiti Sains Malaysia Ethics Com-
mittee and collected after informed consent was obtained.
Human na¨ ıve and memory CD4+ T cells were isolated
from the peripheral blood by immunomagnetic separation.
Brieﬂy, blood was obtained from normal donors, and the
peripheral blood mononuclear cells (PBMCs) were isolated
by the Ficoll gradient centrifugation and incubated with a
panel of biotin-conjugated monoclonal antibodies against
CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCRγδ,
and glycophorin A (Miltenyi Biotec, Germany). CD45RA
and CD45RO microbeads were added reciprocally for the
negative isolation of memory and na¨ ıve CD4+ T cells. The
purity of the isolated na¨ ıve and memory CD4+ T cells were
generally 90–95% as determined by ﬂow cytometric analysis.
2.2. In Vitro Stimulation of Na¨ ıve and Memory CD4+ T
Cells. Na¨ ıve and memory CD4+ T cells were suspended at
2 × 105 cells/mL in complete RPMI 1640 medium (10%
FBS, 100U/mL penicillin, and 100μg/mL streptomycin)
containing CD3/CD28 beads at a 1:1cell/bead ratio in
25cm2 tissue culture ﬂasks. Twenty μM of ciglitazone
solution was added when required at day 0 of culture. This
concentration of ciglitazone was determined based on the
minimumconcentrationrequiredtocauseareductionincell
proliferation as reported in the literature [11, 13, 16]. The
ﬂasks were incubated for 5 days in a humidiﬁed incubator at
37◦Ci n5 %C O 2.
2.3. Proliferation Assay. Na¨ ıve and memory CD4+ T cells
were suspended in 200μL of complete RPMI 1640 medium
at a concentration of 1 × 103/well in triplicate wells of a
96-well ﬂat-bottom plate and stimulated with CD3/CD28
beadsfor5da ysaspreviouslydescribed[17].Whenrequired,
ciglitazone (20μM) was added at day 0 of culture. Ten μLo f
diluted [3H] thymidine (1μC i )w a sa d d e dt oe a c hw e l la t0 ,
24, 48, 72, and 96h after stimulation. After incubation for
another 20–22h, the cells were harvested to represent day 1,
2, 3, 4, and 5, respectively, using the Innotech cell harvester
system (Innotech AG, Switzerland). The incorporation of
[3H] thymidine into DNA was quantiﬁed using a liquid
scintillation counter by Hidex data analysis software (Hidex,
USA).
2.4. Total RNA Extraction and cDNA Synthesis. Total RNA
was extracted from unstimulated and stimulated na¨ ıve and
memory CD4+ T cells with or without ciglitazone treatment
using the RNeasy Mini kit (Qiagen, USA) and QIAshredder
(Qiagen, USA) according to the manufacturer’s instructions.
B r i e ﬂ y ,t h ec e l l sw e r el y s e di nR L Tb u ﬀer and the beads were
depleted using Dynal MPC. The lysed cells were applied onto
the QIAshredder column followed by the RNeasy Mini spin
column after addition of 70% ethanol. The sample column
was then centrifuged, and the ﬂow-through discarded before
700μLo fR W 1b u ﬀer was added into the column. Following
centrifugation, the mixture was washed twice in 500μL
RPE buﬀer before 50μL of RNase free water was added
into the column to dissolve the total RNA. The RNA was
eluted by centrifugation, and its integrity was assessed by
gelelectrophoresiswhileRNApurityandconcentrationwere
measured by spectrophotometry (Biophotometer, Eppen-
dorf, Germany).
Total RNA (between 0.5 to 5 μg) was reverse transcribed
into cDNA using the RevertAid H Minus ﬁrst strand cDNA
synthesis kit (MBI Fermentas, USA) in the presence of 0.5μg
oligo(dT)18 primer in nuclease-free deionized water. The
mixture was ﬁrstly incubated at 70◦Cf o r5m i n u t e s .T h e
reaction mixture was then mixed with 4μLo f5 xr e a c t i o n
buﬀer, 20 unit ribonuclease inhibitor, and 2μLo f1 0 m M
dNTP mix, followed by incubation at 37◦Cf o r5m i n u t e s .
The process of reverse transcription was performed at 42◦C
for 1 hour using 200 unit of RevertAid H Minus M-MuLV.
Finally the process was terminated by heating at 70◦Cf o r
10 minutes. The success of cDNA synthesis was conﬁrmed
by running a PCR using human β-actin primer (Maxim
Biotech, USA).
2.5. Competitive Real-Time PCR. The PPARγ1g e n ew a s
ampliﬁed and quantiﬁed using the following primers/probe:
forward primer 5 -CTT TAT GGA GCC CAA GTT TGAClinical and Developmental Immunology 3
GTT-3 ; reverse primer 5 -GGC TTC ACA TTC AGC AAA
CCT-3  and TaqMan probe 5 -TGC CAA GTC GCT GTC
A T CT A AT T CC A GT G - 3  . The PPARγ2 gene was ampliﬁed
and quantiﬁed using the following primers/probe: forward
primer 5 -GGG TGA AAC TCT GGG AGA TTC TC-3 ;
reverse primer 5 -GAT GCC ATT CTG GCC CAC-3  and
TaqMan probe 5 -TGA CCC AGA AAG CGA TTC CTT
CAC TGA-3 . A total volume of 22.5μLm a s t e rm i x ,w h i c h
included the TaqMan Universal Master Mix (ABI, USA),
TaqMan probe, forward and reverse primers, and sterile
distilled water was added in each well of the PCR plate
prior to the addition of 50ng of target cDNA. The master
mix contains a dye (ROX) for normalization. Five dilutions
of internal standards (plasmids containing the PPARγ1a n d
PPARγ2 genes) were chosen from the range of 10−4 pmol to
10−8 pmol. For nontemplate control (NTC) wells, only water
was added. The reaction plate was sealed with an optical
adhesive cover, centrifuged brieﬂy to avoid any bubbles, and
placed in the real-time PCR apparatus to begin the reaction.
All samples were run in triplicates.
The reaction was initiated at 50◦C for 2min. This
step was required for optimal AmpErase uracil-N-gly-
co-syl-ase (UNG) enzyme activity to decontaminate any
DNA carryover. The temperature was increased to 95◦Cf o r
10min to activate the AmpliTaq Gold enzyme. This was
followed by 45 cycles of denaturation at 95◦Cf o r1 5s e ca n d
primer annealing and extension stages at 60◦Cf o r1 m i n
each.
2.6. Multiplex PCR (MPCR). The expression levels of TGFβ,
IL-1β,I L - 8 ,T N F α,G M - C S F ,a n dI L - 6w e r em e a s u r e di n
unstimulated and stimulated na¨ ıve and memory CD4+ T
cells with or without treatment with ciglitazone using the
MPCR kit for Human Inﬂammatory Cytokines Genes Set-1
(Maxim Biotech, USA). The expression of the house-keeping
gene, GAPDH, was used for normalization. The MPCR was
carried out according to the manufacturer’s instructions.
Brieﬂy, 1x MPCR buﬀer, 1x MPCR primer mix, 2.5 units of
Taq polymerase, and 0.1μg cDNA template were mixed in a
50μL reaction; the optimum annealing temperature for the
MPCR analysis was 66◦Ca n ds u b j e c t e dt o3 5c y c l e so fP C R ,
with denaturing, annealing, and extension temperatures at
94, 58, and 70◦C for 1min each, respectively. Following
MPCR, the products were fractionated electrophoretically in
a 2% agarose gel containing 0.5μg/mL ethidium bromide
and analysed by the Image Master Total Lab v1.00 (Amer-
sham Pharmacia, USA).
2.7. Statistical Analysis. The proﬁles of [3H] thymidine
incorporation of na¨ ıve and memory CD4+ T cells after in
vitro stimulation with or without ciglitazone treatment were
compared and analysed using the Kruskal-Wallis test. The
PPARγ1a n dP P A R γ2 expression and cytokine proﬁles of
unstimulated and stimulated na¨ ıve and memory CD4+ T
cells with or without ciglitazone treatment were compared
and analysed using the Mann-Whitney U test by statistical
program for social science (SPSS) version 11.0 computer
program (SPSS Inc., USA).
3. Results
3.1. Proliferative Response of CD3/CD28-Stimulated Na¨ ıve
and Memory CD4+ T Cells. The proliferative response of
puriﬁed na¨ ıve and memory CD4+ T cells following in vitro
stimulation with CD3/CD28 was assessed. Anti-CD3/CD28
enhanced proliferation in both na¨ ıve and memory CD4+
T cells as depicted by the incorporation of [3H] thymidine
(Figure 1). From day 1 to 5 after stimulation, the cell
proliferation rate increased by more than 20-fold. There was
no signiﬁcant diﬀerence in the proliferation rate between the
na¨ ıve and memory CD4+ T cells. The addition of ciglitazone
decreased the degree of proliferation in na¨ ıve and memory
CD4+ T cells by about 10-fold. Ciglitazone signiﬁcantly
decreased the proliferation rate of activated na¨ ıve CD4+ T
c e l l so nd a y s3 ,4 ,a n d5( P<0.05) and that of activated
memory CD4+ T cells on days 4 and 5 (P<0.05).
3.2. Quantiﬁcation of PPARγ1 and PPARγ2. Unstimulated
na¨ ıve and memory CD4+ T cells expressed low constitutive
levels of PPARγ1 mRNA, whereas stimulated na¨ ıve and
memory CD4+ T cells expressed signiﬁcantly higher levels
of the receptor in both cell types (average of 7 × 104 and
1.2 × 105 mRNA transcripts/μg of total RNA, for na¨ ıve
and memory CD4+ T cells; resp., P>0.05; Figure 2(a)).
Stimulated memory CD4+ T cells displayed higher PPARγ1
expression than na¨ ıve CD4+ T cells (P<0.05). Ciglitazone
treatment signiﬁcantly increased the expression of PPARγ1
by about 70-fold and 160-fold in na¨ ıve and memory CD4+ T
cells (P<0.01), respectively. PPARγ1 expression remained
signiﬁcantly higher in stimulated memory compared to
stimulated na¨ ıve CD4+ T cells in the presence of ciglitazone
(P<0.01).
Unstimulated na¨ ıve and memory CD4+ T cells expressed
10-foldlowerconstitutivelevelsofPPARγ2mRN Acompared
to PPARγ1( Figure 2(b)). Stimulated na¨ ıve and memory
C D 4 +Tc e l l se x p r e s sv e r yh i g hl e v e l so fP P A R γ2m R N Ai n
both cell types (average of 3.9 × 106 and 5.5 × 106 mRNA
transcripts/μg of total RNA, in na¨ ıve and memory CD4+ T
cells,resp.).PPARγ2expressioninstimulatedmemoryCD4+
T cells expressed higher levels of the receptor compared to
na¨ ıve CD4+ T cells. In contrast to PPARγ1, the addition of
ciglitazone signiﬁcantly decreased the expression of PPARγ2
by about 470-fold and 150-fold in na¨ ıve and memory CD4+
Tcells,respectively(P<0.01).However,aftertreatmentwith
ciglitazone, PPARγ2 expression was signiﬁcantly higher in
stimulated memory compared to stimulated na¨ ıve CD4+ T
cells (P<0.01).
Figure 3 shows an example of a gel electrophoresis of
the MPCR products of selected inﬂammatory cytokines in
unstimulated and stimulated na¨ ıve and memory CD4+ T
cells with or without ciglitazone treatment. The expression
ofvariouscytokineswascomparedbydensitometricanalyses
and expressed as a ratio of GAPDH. The results were then
plotted as histograms as depicted in Figure 4.
As shown in Figure 4(a), the expression levels of TGFβ
gene were higher in unstimulated na¨ ıve and memory CD4+
T cells but decreased signiﬁcantly in their stimulated state
(P<0.01). The addition of ciglitazone did not signiﬁcantly4 Clinical and Developmental Immunology
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Figure 1: Proliferation assay. [3H] thymidine incorporation of na¨ ıve (CD45RA+) and memory (CD45RO+) CD4+ T cells following in vitro
stimulation with CD3/CD28 beads, in the presence or absence of ciglitazone. Data are expressed as the mean cpm of triplicate cultures ±
SEM. The experiments were repeated three times. Statistical analyses were performed using the Kruskal-Wallis test.∗P<0.05 (for na¨ ıve
CD4+ T cells) or #P<0.05 (for memory CD4+ T cells) of ciglitazone-treated, compared to untreated stimulated cells.
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Figure 2: PPARγ1a n dP P A R γ2 mRNA expression. (a) PPARγ1 and (b) PPARγ2 gene expression levels in unstimulated (open bar, n = 13)
and stimulated (grey bar, n = 13) na¨ ıve and memory CD4+ T cells or those treated with ciglitazone (solid bar, n = 8). The PPARγ1a n d
PPARγ2 gene expression levels were calculated as the number of mRNA transcripts per μg total RNA. The data plotted is the mean mRNA
transcripts ± SEM. Statistical analyses were performed using the Mann-Whitney U test. ∗P<0.05; ∗∗P<0.01—signiﬁcantly diﬀerent from
unstimulated cells. #P<0.05; ##P<0.01—signiﬁcantly diﬀerent from CD3/CD28–stimulated cells. ¶P<0.05—signiﬁcantly diﬀerent from
correspondingly treated CD45RA+ cells.
alter the expression of TGFβ in both stimulated cells. IL-1β
gene expression was also higher in unstimulated na¨ ıve and
memory CD4+ T cells but decreased signiﬁcantly in their
stimulated state (P<0.01). Ciglitazone further decreased
the expression of IL-1β in stimulated na¨ ıve (P<0.01) but
n o ti ns t i m u l a t e dm e m o r yC D 4 +Tc e l l s( Figure 4(b)). IL-8
gene was expressed at low levels in unstimulated na¨ ıve and
memory CD4+ T cells but signiﬁcantly increased in both cell
t y p e su p o na c t i v a t i o n( P<0.01). IL-8 expression decreased
in memory and na¨ ıve CD4+ T cells to its unstimulated states
upon addition of ciglitazone (P<0.01) (Figure 4(c)).
Figure 4(d) shows the de novo TNFα expression in
stimulated na¨ ıve and memory CD4+ T cells. There was no
signiﬁcant diﬀerence in the expression of TNFα in both cellClinical and Developmental Immunology 5
12345678
GAPDH (921 bp)
TNFα (680 bp)
IL1β (555 bp)
GM-CSF (424 bp)
IL6 (360 bp)
IL8 (300 bp)
TGFβ (161 bp)
Figure 3: Example of multiplex PCR readout of inﬂammatory cytokine gene expression. Lane 1: unstimulated na¨ ı v eC D 4 +Tc e l l s .L a n e2 :
stimulated na¨ ıve CD4+ T cells. Lane 3: stimulated na¨ ıve CD4+ T cells + ciglitazone. Lane 4: unstimulated memory CD4+ T cells. Lane 5:
stimulated memory CD4+ T cells. Lane 6: stimulated memory CD4+T cells + ciglitazone. Lane 7: positive control. Lane 8:100bp marker.
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Figure 4: Inﬂammatory cytokine expression.Relative mRNA expression levels of selected cytokine genes in na¨ ıve and memory CD4+ T cells
following CD3/CD28 stimulation in the presence or absence of ciglitazone (n = 5). Untreated cells (open bar), stimulated cells (grey bar),
and ciglitazone-treated cells (solid bar) were assessed for their relative expression of (a) TGFβ,( b )I L - 1 β,( c )I L - 8 ,( d )T N F α, (e) GM-CSF,
and (f) IL-6, as a ratio of GAPDH. Statistical analyses were performed using the Mann-Whitney U test. ∗P<0.05, ∗∗P<0.01. #Signiﬁcance
levels cannot be analyzed because the gene expression was not detectable.
types after activation. Ciglitazone signiﬁcantly decreased the
expression of TNFα in stimulated memory (P<0.01) but
not in na¨ ıve CD4+ T cells. GM-CSF was also expressed
in stimulated na¨ ıve and memory CD4+ T cells but not in
their unstimulated state. There was no signiﬁcant diﬀerence
in the expression of GM-CSF in both cell types after
activation. GM-CSF expression was signiﬁcantly reduced in
stimulated na¨ ıve and memory CD4+ T cells in the presence
of ciglitazone (P<0.01; Figure 4(e)). Figure 4(e) shows that
only stimulated na¨ ıve and memory CD4+ T cells expressed
IL-6. The addition of ciglitazone completely abolished the
expression of IL-6in both stimulated cells.The resultsclearly
show de novo expression of TNF-α,G M - C S F ,a n dI L - 6u p o n
activation of na¨ ıve and memory CD4+ T cells.
4. Discussion
It is now established that PPARγ is involved in the regulation
of T-cell function, as well as macrophage and dendritic cell
activities [18–20]. In view of the fact that human na¨ ıve
and memory CD4+ T cells diﬀer in the requirements for
activation and magnitude of their cellular responses [21]6 Clinical and Developmental Immunology
and autoreactivity [3, 4], we investigated the eﬀect of the
PPARγ agonist, ciglitazone, on the mRNA expression of
PPARγ1a n dP P A R γ2 and on a number of inﬂammatory
cytokines produced by these cells. No previous studies on the
expression of PPARγ1a n dP P A R γ2i nh u m a nn a ¨ ıve and
memory CD4+ T cells have been reported.
Consistent with previous reports [11, 13, 16, 20], cigli-
tazone treatment resulted in a tenfold reduction in the
proliferative response of both CD3/CD28-stimulated na¨ ıve
andmemoryCD4+T-cellsubsets.Inhibitionofproliferation
in activated na¨ ıve T cells by PPARγ agonists, such as
ciglitazone, has been previously attributed to apoptosis [16],
although whether this occurs via a PPARγ-dependent or
independent pathway remains to be elucidated.
Using RT-PCR, PPARγ1a n dP P A R γ2w e r ef o u n dt ob e
highly expressed in both na¨ ıve and memory CD4+ T cells
upon activation through the TCR and costimulatory CD28
pathway. Consistent with previous ﬁndings [21], only low
expression levels of both transcripts in unstimulated CD4+
Tcellswererecorded.Interestingly, previousstudiesreported
that PPARγ is constitutively expressed in human peripheral
blood mononuclear cells [6, 22]. However, this may be due
to its expression by other cell subsets in the mononuclear cell
populationsuchasmonocytes[18],Bc ells[23],andNKcells
[24].
It is interesting to note the low level expression of
PPARγ1a n dP P A R γ2i nr e s t i n gh u m a nn a ¨ ıve and memory
CD4+ T cells. This may suggest that their roles are primarily
in the regulation of responding T cells. It is also noteworthy
that higher levels of both transcripts are found in activated
memory CD4+ T cells as opposed to their low level expres-
sion in activated na¨ ıve T cells, suggesting that regulation of
memory CD4+ T cells may require higher-level expression
of PPARγ compared to na¨ ıve CD4+ cells.
Treatment with ciglitazone enhanced the expression of
PPARγ1 but greatly diminished that of PPARγ2i nb o t h
the na¨ ıve and memory CD4+ T cells. Previous studies have
reported that PPARγ agonists such as troglitazone [12]a n d
pioglitazone [22] attenuated the expression of the receptor.
Here, we report that ciglitazone enhances the expression of
PPARγ1 but greatly diminishes the expression of PPARγ2
in both na¨ ıve and memory CD4+ T cells. This apparent
discrepancy can be attributed to the fact that the above
studies did not distinguish between the two PPARγ isoforms.
PPARγ1 can be regarded as a “subset” of PPARγ2w h i c h
contains additional 28 amino acids at its N-terminus.
Thus, measuring PPARγ expression without distinguishing
the two isoforms may not provide an accurate reﬂection
of the receptor’s role in immune regulation. The lack of
speciﬁc antibodies against PPARγ1 has however impeded
our attempt to diﬀerentiate the protein expression of these
receptors in the current study. The decrease in PPARγ2
expression cannot be attributed to cell death via apoptosis
[16] since the expression of PPARγ1 was enhanced and that
the cell recovery after 5 days was above 90% (results not
shown).
The diﬀerent roles played by the two PPARγ isoforms in
CD4+ T-cell regulation can be inferred from their expression
levels displayed at pre- and posttreatment with ciglitazone.
Thus, although the fold increase in PPARγ2 expression was
higher than that observed for PPARγ1, it was almost com-
pletely abrogated upon addition of ciglitazone. A previous
report [12] showed that troglitazone and 15d-PGJ2 inhibited
IL-2 production in the PPARγ2-expressing but not in
PPARγ2-nonexpressing transfected Jurkat T cells, suggesting
that PPARγ2 is involved in regulating T cell function. The
almost complete abrogation of PPARγ2 expression following
treatment with ciglitazone is interesting and requires further
investigations, such as inhibition studies. The present lack
of speciﬁc chemical inhibitors for PPARγ2, however, would
complicate such studies for the time being.
As mentioned above, activation of PPARγ by its ligands
has been shown to induce apoptosis in T cells [16, 25].
Hence the question arises whether cells that express higher
levels of PPARγ2 are more prone to apoptosis, resulting in
the preferential “elimination” of PPARγ2-expressing cells.
Single-cell analyses, including the measurement of PPARγ1
and PPARγ2 protein levels, should be carried out to address
these questions. However, as anti-PPARγ1 antibodies are not
available, such experiments may prove currently challenging.
It will also be important to investigate the molecular regu-
lation of PPARγ1a n dP P A R γ2 promoters in order to under-
stand the possible diﬀerential control of their expression.
Since diﬀerential expression of PPAR has been shown to
correlate with selected cytokine production [26, 27] and that
na¨ ıve and memory CD4+ T cells may play a diﬀerential role
inautoimmunity[3,4],thelevelofvariousproinﬂammatory
cytokines that were expressed in the resting and activated
na¨ ıve and memory CD4+ T cells with or without treatment
with ciglitazone was subsequently determined. While TGFβ,
IL-8, and IL-1β expression in resting na¨ ıve and memory
CD4+ T cells has previously been reported [28], their ex-
pression in activated na¨ ıve and memory CD4+ T cells has
not been previously studied.
Activated na¨ ıve and memory CD4+ T cells displayed
low expression levels of both TGF-β and IL-1β, further
reduced upon stimulation with ciglitazone (in the case of
IL-1β, further reduction was only observed in activated
na¨ ıve CD4+ T cells). These ﬁndings are in agreement
with those previously reported [13, 19]. Unstimulated na¨ ıve
and memory CD4+ T cells displayed low levels of IL-8
which signiﬁcantly increased upon activation. However, the
addition of ciglitazone dramatically reduced IL-8 expression.
Thisobservationisincontrasttoapreviousﬁndingthat15d-
PGJ2, another PPARγ ligand, induced the expression of IL-
8 in human T cells via a PPARγ-independent manner [29].
Thus there may be distinct response against diﬀerent ligands
with regard to the function of these receptors. Future studies
will, therefore, need to include the use of several PPARγ
ligands to determine the detailed mechanistic roles of the
receptors in immune response.
Activation of both na¨ ıve and memory CD4+ T cells
induced de novo expression of TNFα,G M - C S F ,a n dI L - 6 ,
whereas treatment of these activated cells with ciglitazone
diminished TNFαandGM-CSF expression, andtotallyabro-
gated IL-6 expression. Previous studies showed signiﬁcant
reduction in the release of LPS-stimulated TNFα upon acti-
vation of placental, amnion, and choriodecidual, tissues withClinical and Developmental Immunology 7
both 15d-PGJ2 and troglitazone [30]. Ciglitazone, troglita-
zone, and 15d-PGJ2 also inhibited RSV-induced release of
TNFα in A549 epithelial cells [31]. As previously reported
[19], the expression of GM-CSF in activated na¨ ıve and mem-
ory CD4+ T cells may play a role in inducing the expression
of PPARγ1a n dP P A R γ2 in both activated cells. Reduction of
GM-CSF expression after ciglitazone treatment has also been
reported in mast cells where a PPARγ agonist decreased the
antigen-induced GM-CSF production [32].
The present observation that IL-6 is produced in similar
levelsbybothna¨ ıveandmemoryCD4+Tcellshaspreviously
been reported [33]. IL-6 plays an essential role in activating
na¨ ıve and memory CD4+ T cells through the CD2 molecule
[34]. Unlike na¨ ıve T cells, CD4 memory T cells can undergo
proliferation when stimulated with anti-CD2 in the absence
of APCs since they are able to use self-produced IL-6 [35].
However, the current study shows that activation of na¨ ıve
CD4+ T cells via the CD3 and CD28 pathways also induced
the production of IL-6. This may have occurred through
the engagement of the CD28 molecule which may act by
amplifying the activation signals in an autocrine fashion.
Ap r e v i o u sr e p o r t[ 36] supports our observation that
ciglitazone completely abolished the expression of IL-6 in
activated na¨ ıve and memory CD4+ T cells. There is also
evidence that chronic IL-6 treatment suppressed the expres-
sion of PPARγ [26], and the suppression of PPARγ func-
tions resulted in excessive production of the cytokine [37].
The mechanism through which ciglitazone aﬀects cytokine
production remains to be elucidated. There is evidence [11,
12, 19] to suggest that this may occur through activation
of transcription factors such as AP-1, STAT-1, and NF-κB.
Since there are no reports to suggest that the cis-element
of inﬂammatory cytokine genes contains PPARγ binding
site, inhibition may occur indirectly via transrepression as
described above [13]. It was also reported that 15d-PGJ2
treatment rendered IκB resistant to degradation upon cel-
lular activation [38], hence, preventing NF-κB activation.
However, since ciglitazone is structurally diﬀerent from 15d-
PGJ2, the mechanism of inhibition of NF-κB and AP-1
activity by ciglitazone may diﬀer from its inhibition by 15d-
PGJ2.
5. Conclusions
PPARγ1a n dP P A R γ2h a v ed i ﬀerential regulatory roles in
responding na¨ ıve and memory CD4+ T cells. Overall, na¨ ıve
CD4+ T cells seem to be more sensitive to PPARγ activation,
although further studies need to be carried out to conﬁrm
this observation. The availability of speciﬁc antibodies and
speciﬁc antagonists against these two isoforms is needed to
enable a more precise elucidation of their purported dif-
ferential functions in T-cell regulation. In addition, the
precise mechanism of how PPARγ1a n dP P A R γ2 regulate the
response of na¨ ıve and memory cells or the immune response
in general will require further investigations utilizing single-
cell analytical tools.
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